Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells

E. Golovina, T. Heizer, L. Daumova, M. Bajecny, S. Fontana, V. Griggio, R. Jones, M. Coscia, C. Riganti, K. Savvulidi Vargova

. 2024 ; 24 (1) : 251. [pub] 20240718

Status not-indexed Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24018210

Grant support
START/MED/089 and PRIMUS/17/MED/16 Elena Golovina
START/MED/089 Tomas Heizer
START/MED/089 Lenka Daumova
PROGRES Q26/LF1 Martin Bajecny
IG21408 Simona Fontana
IG21408 Valentina Griggio
IG21408 Rebecca Jones
IG21408 Marta Coscia
IG21408 Chiara Riganti
START/MED/089 and PRIMUS/17/MED/16 Karina Savvulidi Vargova

Hypoxia represents one of the key factors that stimulates the growth of leukemic cells in their niche. Leukemic cells in hypoxic conditions are forced to reprogram their original transcriptome, miRNome, and metabolome. How the coupling of microRNAs (miRNAs)/mRNAs helps to maintain or progress the leukemic status is still not fully described. MiRNAs regulate practically all biological processes within cells and play a crucial role in the development/progression of leukemia. In the present study, we aimed to uncover the impact of hsa-miR-155-5p (miR-155, MIR155HG) on the metabolism, proliferation, and mRNA/miRNA network of human chronic lymphocytic leukemia cells (CLL) in hypoxic conditions. As a model of CLL, we used the human MEC-1 cell line where we deleted mature miR-155 with CRISPR/Cas9. We determined that miR-155 deficiency in leukemic MEC-1 cells results in lower proliferation even in hypoxic conditions in comparison to MEC-1 control cells. Additionally, in MEC-1 miR-155 deficient cells we observed decreased number of populations of cells in S phase. The miR-155 deficiency under hypoxic conditions was accompanied by an increased apoptosis. We detected a stimulatory effect of miR-155 deficiency and hypoxia at the level of gene expression, seen in significant overexpression of EGLN1, GLUT1, GLUT3 in MEC-1 miR-155 deficient cells. MiR-155 deficiency and hypoxia resulted in increase of glucose and lactate uptake. Pyruvate, ETC and ATP were reduced. To conclude, miR-155 deficiency and hypoxia affects glucose and lactate metabolism by stimulating the expression of glucose transporters as GLUT1, GLUT3, and EGLN1 [Hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2)] genes in the MEC-1 cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018210
003      
CZ-PrNML
005      
20241016081830.0
007      
ta
008      
241008s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12935-024-03437-8 $2 doi
035    __
$a (PubMed)39020347
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Golovina, Elena $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells / $c E. Golovina, T. Heizer, L. Daumova, M. Bajecny, S. Fontana, V. Griggio, R. Jones, M. Coscia, C. Riganti, K. Savvulidi Vargova
520    9_
$a Hypoxia represents one of the key factors that stimulates the growth of leukemic cells in their niche. Leukemic cells in hypoxic conditions are forced to reprogram their original transcriptome, miRNome, and metabolome. How the coupling of microRNAs (miRNAs)/mRNAs helps to maintain or progress the leukemic status is still not fully described. MiRNAs regulate practically all biological processes within cells and play a crucial role in the development/progression of leukemia. In the present study, we aimed to uncover the impact of hsa-miR-155-5p (miR-155, MIR155HG) on the metabolism, proliferation, and mRNA/miRNA network of human chronic lymphocytic leukemia cells (CLL) in hypoxic conditions. As a model of CLL, we used the human MEC-1 cell line where we deleted mature miR-155 with CRISPR/Cas9. We determined that miR-155 deficiency in leukemic MEC-1 cells results in lower proliferation even in hypoxic conditions in comparison to MEC-1 control cells. Additionally, in MEC-1 miR-155 deficient cells we observed decreased number of populations of cells in S phase. The miR-155 deficiency under hypoxic conditions was accompanied by an increased apoptosis. We detected a stimulatory effect of miR-155 deficiency and hypoxia at the level of gene expression, seen in significant overexpression of EGLN1, GLUT1, GLUT3 in MEC-1 miR-155 deficient cells. MiR-155 deficiency and hypoxia resulted in increase of glucose and lactate uptake. Pyruvate, ETC and ATP were reduced. To conclude, miR-155 deficiency and hypoxia affects glucose and lactate metabolism by stimulating the expression of glucose transporters as GLUT1, GLUT3, and EGLN1 [Hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2)] genes in the MEC-1 cells.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Heizer, Tomas $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Daumova, Lenka $u Institute Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
700    1_
$a Bajecny, Martin $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Fontana, Simona $u Oncological Pharmacology Laboratory, Department of Oncology, University of Torino, Torino, Italy
700    1_
$a Griggio, Valentina $u Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città Della Salute E Della Scienza Di Torino, Torino, Italy
700    1_
$a Jones, Rebecca $u Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città Della Salute E Della Scienza Di Torino, Torino, Italy
700    1_
$a Coscia, Marta $u Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città Della Salute E Della Scienza Di Torino, Torino, Italy
700    1_
$a Riganti, Chiara $u Oncological Pharmacology Laboratory, Department of Oncology, University of Torino, Torino, Italy
700    1_
$a Savvulidi Vargova, Karina $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. vargova.mmbd@gmail.com
773    0_
$w MED00008210 $t Cancer cell international $x 1475-2867 $g Roč. 24, č. 1 (2024), s. 251
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39020347 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081825 $b ABA008
999    __
$a ok $b bmc $g 2196495 $s 1230161
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 24 $c 1 $d 251 $e 20240718 $i 1475-2867 $m Cancer cell international $n Cancer Cell Int $x MED00008210
GRA    __
$a START/MED/089 and PRIMUS/17/MED/16 $p Elena Golovina
GRA    __
$a START/MED/089 $p Tomas Heizer
GRA    __
$a START/MED/089 $p Lenka Daumova
GRA    __
$a PROGRES Q26/LF1 $p Martin Bajecny
GRA    __
$a IG21408 $p Simona Fontana
GRA    __
$a IG21408 $p Valentina Griggio
GRA    __
$a IG21408 $p Rebecca Jones
GRA    __
$a IG21408 $p Marta Coscia
GRA    __
$a IG21408 $p Chiara Riganti
GRA    __
$a START/MED/089 and PRIMUS/17/MED/16 $p Karina Savvulidi Vargova
LZP    __
$a Pubmed-20241008

Find record

Citation metrics

Archiving options